feed,title,long_url,short_url
Benzinga,Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment,https://benzinga.com/general/biotech/24/05/38793420/merck-halts-skin-cancer-drug-trial-on-high-discontinuation-rate-a-setback-in-high-risk-melanoma-t,https://da.gd/3gTjgu
